• ACADIA Pharmaceuticals received a USPTO Notice of Allowance for a U.S. patent covering weight-banded dosing of trofinetide for Rett syndrome.
• Expected patent term, including six months of pediatric exclusivity, runs through March 28, 2041, extending protection by nearly five years.
• Trofinetide also has a U.S. method-of-use patent for Rett syndrome that expires in July 2036.
• Trofinetide is marketed in the U.S. as DAYBUE and DAYBUE STIX for adults and pediatric patients ages 2 and older.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260928764044) on September 28, 2026, and is solely responsible for the information contained therein.